# Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Canonical URL: https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates
Ticker: IOVA
Company: Iovance Biotherapeutics, Inc.
Source: Iovance Biotherapeutics, Inc.
Published: 2026-05-07 11:05 EST
Original Source URL: https://ir.iovance.com
## Summary

1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M   40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.

## Article Body
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M   40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
## Recent Company News
- 2026-06-03 20:05 EST — [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-01 11:30 EST — [Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001) — Source: Iovance Biotherapeutics, Inc.
- 2026-05-21 12:05 EST — [Iovance Biotherapeutics to Present at Upcoming Conference](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conference) — Source: Iovance Biotherapeutics, Inc.
- 2026-05-07 11:05 EST — [Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates) — Source: Iovance Biotherapeutics, Inc.
- 2026-04-27 12:01 EST — [Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-report-first-quarter-2026-financial-results-and-corporate-updates-on-thursday-may-7-2026) — Source: Iovance Biotherapeutics, Inc.
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)